UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530)

Journal of medicinal chemistry, 2020-10, Vol.63 (19), p.11034-11044

2020

Volltextzugriff (PDF)

Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir

Drug metabolism and disposition, 2017-07, Vol.45 (7), p.755-764

2017

Volltextzugriff (PDF)

Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir

The Journal of pharmacology and experimental therapeutics, 2019-08, Vol.370 (2), p.278

2019

Volltextzugriff (PDF)

Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound—The Venetoclax Story

Journal of pharmaceutical sciences, 2018-01, Vol.107 (1), p.495-502

2018

Volltextzugriff (PDF)

Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes

Drug metabolism and disposition, 2008-01, Vol.36 (1), p.198

2008

Volltextzugriff (PDF)

Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study

Clinical and translational science, 2021-01, Vol.14 (1), p.373-381

2021

Volltextzugriff (PDF)

No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted With Ritonavir or Cobicistat

Journal of pharmaceutical sciences, 2019-09, Vol.108 (9), p.3118-3123

2019

Volltextzugriff (PDF)

Prediction of Clinical Drug–Drug Interactions of Veliparib (ABT-888) with Human Renal Transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)

Journal of pharmaceutical sciences, 2013-12, Vol.102 (12), p.4426-4432

2013

Volltextzugriff (PDF)

Quantitation of Plasma Membrane Drug Transporters in Kidney Tissue and Cell Lines Using a Novel Proteomic Approach Enabled a Prospective Prediction of Metformin Disposition

Drug metabolism and disposition, 2021-10, Vol.49 (10), p.938-946

2021

Volltextzugriff (PDF)

Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors

Bioorganic & medicinal chemistry letters, 2020-04, Vol.30 (7), p.126986, Article 126986

2020

Volltextzugriff (PDF)

Synthesis and evaluation of 2′-dihalo ribonucleotide prodrugs with activity against hepatitis C virus

Bioorganic & medicinal chemistry, 2020-01, Vol.28 (1), p.115208, Article 115208

2020

Volltextzugriff (PDF)

Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions

Xenobiotica, 2017-01, Vol.47 (9), p.825-832

2017

Volltextzugriff (PDF)

In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia

Xenobiotica, 2014-03, Vol.44 (3), p.276-282

2014

Volltextzugriff (PDF)

Animal models for drug transporters

Drug metabolism and pharmacokinetics, 2019-01, Vol.34 (1), p.S1-S1

Bow, Daniel

2019

Volltextzugriff (PDF)

Quantitation of plasma membrane drug transporters enables bottom-up PBPK modeling of transporter substrates

Drug metabolism and pharmacokinetics, 2019-01, Vol.34 (1), p.S74-S74

2019

Volltextzugriff (PDF)

The impact of plasma protein binding on the renal transport of organic anions

The Journal of pharmacology and experimental therapeutics, 2006-01, Vol.316 (1), p.349

2006

Volltextzugriff (PDF)

Validation of a total IC 50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions

Xenobiotica, 2017-09, Vol.47 (9), p.825-832

2017

Volltextzugriff (PDF)

Molecular Aspects of the Transport and Toxicity of Ochratoxin A

Accounts of chemical research, 2004-11, Vol.37 (11), p.874-881

2004

Volltextzugriff (PDF)

Venetoclax: DMPK challenges and opportunities from discovery to market

Drug metabolism and pharmacokinetics, 2018-01, Vol.33 (1), p.S6-S6

Bow, Daniel A.J.

2018

Volltextzugriff (PDF)

In vitro characterization of drug metabolizing enzymes and transporters to enable a mechanistic drug-drug interaction assessment for venetoclax

Drug metabolism and pharmacokinetics, 2017-01, Vol.32 (1), p.S51-S51

2017

Volltextzugriff (PDF)

Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat

AIDS reviews, 2015-01, Vol.17 (1), p.37-46

2015

Volltextzugriff (PDF)

Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Nav1.7/ Nav1.8 blockers for the treatment of pain

Bioorganic & medicinal chemistry, 2022-06, Vol.63, p.116743-116743, Article 116743

2022

Volltextzugriff (PDF)

Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Na v 1.7/ Nav1.8 blockers for the treatment of pain

Bioorganic & medicinal chemistry, 2022-06, Vol.63, p.116743

2022

Volltextzugriff (PDF)

Pharmacokinetic Enhancement in HIV Antiretroviral Therapy: A Comparison of Ritonavir and Cobicistat

AIDS reviews, 2015-01, Vol.17 (1), p.1-1

2015

Volltextzugriff (PDF)

Molecular aspects of the transport and toxicity of ochratoxin A

The New England journal of medicine, 2004-11, Vol.351 (20), p.874

2004

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(48)

Publikationsform

Sprache

Englisch
(56)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530)

Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir

Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir

Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound—The Venetoclax Story

Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes

Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study

No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted With Ritonavir or Cobicistat

Prediction of Clinical Drug–Drug Interactions of Veliparib (ABT-888) with Human Renal Transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)

Quantitation of Plasma Membrane Drug Transporters in Kidney Tissue and Cell Lines Using a Novel Proteomic Approach Enabled a Prospective Prediction of Metformin Disposition

Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors

Synthesis and evaluation of 2′-dihalo ribonucleotide prodrugs with activity against hepatitis C virus

Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions

In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia

Animal models for drug transporters

Quantitation of plasma membrane drug transporters enables bottom-up PBPK modeling of transporter substrates

The impact of plasma protein binding on the renal transport of organic anions

Validation of a total IC 50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions

Molecular Aspects of the Transport and Toxicity of Ochratoxin A

Venetoclax: DMPK challenges and opportunities from discovery to market

In vitro characterization of drug metabolizing enzymes and transporters to enable a mechanistic drug-drug interaction assessment for venetoclax

Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat

Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Nav1.7/ Nav1.8 blockers for the treatment of pain

Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Na v 1.7/ Nav1.8 blockers for the treatment of pain

Pharmacokinetic Enhancement in HIV Antiretroviral Therapy: A Comparison of Ritonavir and Cobicistat

Molecular aspects of the transport and toxicity of ochratoxin A

Suchergebnisse filtern